Tech Company Financing Transactions
Terrestrial Bio Funding Round
Terrestrial Bio closed a $12 million investment round on 5/22/2024. Investors included Engine Ventures, Global Health Investment Corporation and Mission BioCapital.
Transaction Overview
Company Name
Announced On
5/22/2024
Transaction Type
Venture Equity
Amount
$12,000,000
Round
Undisclosed
Proceeds Purpose
The company intends to use the funds to advance GLP-1, continue in vivo work with mRNA, and expand and scale manufacturing process capabilities in support of new partnerships to deliver next generation vaccines and therapeutics.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
127 Western Ave.
Boston, MA 02134
USA
Boston, MA 02134
USA
Phone
Website
Email Address
Not Recorded
Overview
Terrestrial Bio, Inc. (formerly Vaxess Technologies) is a clinical-stage biotechnology company focused on transforming the delivery of next-generation therapies. The company aims to make therapeutic delivery more patient-friendly and accessible by replacing traditional needles with its proprietary MIMIX� microarray patch (MAP) platform.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Rachel Sha
Chief Technical Officer
Mark Tracy
Co-Founder
Fiorenzo Omenetto
VP - Bus. Development
Livio Valenti
VP - R & D
Jonathan Kluge
VP - R & D
Kathryn Kosuda
Browse more venture capital transactions:
Prev: 5/22/2024: Superpower venture capital transaction
Next: 5/22/2024: SixPeaks Bio venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC transactions reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs